| Similar Articles |
|---|
 |
The Motley Fool
January 25, 2006
Brian Gorman |
PAREXEL Recovers The clinical research services company is in better shape, but it still has progress to make. Investors should approach the company with some caution.   |
The Motley Fool
July 22, 2009
Robert Steyer |
Canaries in the Drug Coal Mine Contract research organizations like Pharmaceutical Product Development and ICON reflect an ailing drug industry. |
The Motley Fool
October 29, 2009
Robert Steyer |
Pharma Researchers Need a Cure As the industry changes, Pharmaceutical Product Development and Parexel International struggle. |
The Motley Fool
June 10, 2005
Brian Gorman |
PAREXEL's New Risk The contract pharmaceutical research services provider is realigning its business, but even with reduced U.S. operations, it faces increased risk. Investors, beware. |
The Motley Fool
August 3, 2004
Brian Gorman |
PAREXEL Gets Leaner The research services provider continues to improve operating performance, but that might not affect its stock price. |
The Motley Fool
August 11, 2006
Brian Gorman |
PAREXEL Takes It Up a Notch The company reported higher profitability in the fourth quarter, and management expects the trend to continue. Investors, is this worth a closer look? |
